Insmed reported $-106255000 in Operating Profit for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Profit Change
Acelrx Pharmaceuticals ACRX:US $ -10015000 873K
Alexion Pharmaceuticals ALXN:US $ 636.2M 14.1M
Arena Pharmaceuticals ARNA:US $ -144.39M 12.4M
Biomarin Pharmaceutical BMRN:US $ 11.67M 13.41M
Cytokinetics CYTK:US $ -54.8M 14.19M
Dynavax Technologies DVAX:US $ 3.94M 24.59M
Flexion Therapeutics FLXN:US $ -16882000 6.26M
Gilead Sciences GILD:US $ 2246M 644M
Heron Therapeutics HRTX:US $ -60.47M 8.36M
Insmed INSM:US $ -106255000 22.42M
Mirati Therapeutics MRTX:US $ -164.19M 31.76M
Novartis NVS:US $ 3479M 1064M
Regeneron Pharmaceuticals REGN:US $ 3347.2M 2234.5M
Sarepta Therapeutics SRPT:US $ -167.57M 15.71M
Seattle Genetics SGEN:US $ -89.6M 32.82M
Ultragenyx Pharmaceutical RARE:US $ -82.78M 23.79M
Vertex Pharmaceuticals VRTX:US $ -37.96M 925.79M